VRCA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
VRCA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Verrica Pharmaceuticals's Beginning Cash Position for the quarter that ended in Sep. 2024 was $31.93 Mil.
Verrica Pharmaceuticals's quarterly Beginning Cash Position declined from Mar. 2024 ($69.55 Mil) to Jun. 2024 ($48.94 Mil) and declined from Jun. 2024 ($48.94 Mil) to Sep. 2024 ($31.93 Mil).
Verrica Pharmaceuticals's annual Beginning Cash Position increased from Dec. 2021 ($10.69 Mil) to Dec. 2022 ($15.75 Mil) and increased from Dec. 2022 ($15.75 Mil) to Dec. 2023 ($34.27 Mil).
The historical data trend for Verrica Pharmaceuticals's Beginning Cash Position can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Verrica Pharmaceuticals Annual Data | |||||||||||||||||
Trend | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Beginning Cash Position | Get a 7-Day Free Trial | 10.27 | 9.24 | 10.69 | 15.75 | 34.27 |
Verrica Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Beginning Cash Position | Get a 7-Day Free Trial | 55.14 | 84.31 | 69.55 | 48.94 | 31.93 |
Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.
Thank you for viewing the detailed overview of Verrica Pharmaceuticals's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.
Ted White | director, officer: President and CEO | C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380 |
Terry Kohler | officer: Chief Financial Officer | C/O VERRICA PHARMACEUTICALS INC., 44 WEST GAY STREET, SUITE 400, WEST CHESTER PA 19380 |
Christopher G. Hayes | officer: General Counsel | C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380 |
Joe Bonaccorso | officer: Chief Commercial Officer | C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380 |
Gary Goldenberg | director | C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380 |
Perceptive Life Sciences Master Fund Ltd | 10 percent owner | C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Paul B Manning | director, 10 percent owner | 200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902 |
A Brian Davis | officer: Chief Financial Officer | C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380 |
Craig Ballaron | director | C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380 |
Stalfort John A Iii | director | C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902 |
Lawrence Eichenfield | director | C/O FORTE BIOSCIENCES, INC., 1124 W. CARSON ST., MRL BLDG 3-320, TORRANCE CA 90502 |
Diem Nguyen | director | C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380 |
Matt Davidson | 10 percent owner | C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380 |
Linda Palczuk | officer: Chief Operating Officer | 7015 ALBERT EINSTEIN DRIVE, COLUMBIA MD 21046 |
Chris Degnan | officer: Chief Financial Officer | C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380 |
From GuruFocus
By Marketwired • 11-21-2024
By Marketwired • 05-08-2024
By Marketwired • 05-09-2024
By GuruFocus News • 10-09-2024
By Business Wire • 02-14-2024
By GuruFocus Research • 03-01-2024
By Marketwired • 12-06-2024
By Business Wire • 10-11-2024
By GuruFocus Research • 02-29-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.